A review of upadacitinib in rheumatoid arthritis

Modern Rheumatology
Yoshiya Tanaka

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease primarily affecting the joints and is associated with significant levels of disability and reduced quality of life. Janus kinase (JAK) inhibitors are a relatively new class of small molecule oral treatments and offer an alternative for patients with RA who do not respond to conventional or biologic therapy. Upadacitinib is a JAK inhibitor engineered to be selective for JAK1, and has recently been approved for use in patients with moderate-to-severe RA. The purpose of this article is to provide a comprehensive review of upadacitinib, including preclinical development and characterization, phase I and II studies, and the phase III SELECT program. Ongoing trials of upadacitinib in additional indications, including spondyloarthritis, inflammatory bowel disease, and atopic dermatitis, are also discussed.

References

Mar 18, 2009·Immunological Reviews·Kamran GhoreschiJohn J O'Shea
Apr 4, 2012·Annals of the Rheumatic Diseases·Y TanakaK Yamaoka
Apr 3, 2013·Annals of the Rheumatic Diseases·John J O'SheaArian Laurence
Sep 28, 2013·Annals of the Rheumatic Diseases·Josef S SmolenRobert Landewé
Jun 19, 2014·The New England Journal of Medicine·Eun Bong LeeUNKNOWN ORAL Start Investigators
Jan 15, 2015·Annual Review of Medicine·John J O'SheaArian Laurence
May 15, 2015·Annals of the Rheumatic Diseases·Josef S SmolenDesirée van der Heijde
Dec 4, 2015·Nature Reviews. Rheumatology·Daniella M SchwartzJohn J O'Shea
Oct 30, 2016·Lancet·Josef S SmolenIain B McInnes
Nov 16, 2016·Patient Preference and Adherence·Rieke AltenHans-Dieter Nolting
Mar 3, 2017·Nature Reviews. Rheumatology·Kevin L Winthrop
Apr 25, 2017·Open Access Rheumatology : Research and Reviews·Alfonso E BelloPetros Efthimiou
Jun 15, 2017·Lancet·Iain B McInnes, Georg Schett
Aug 29, 2017·Arthritis & Rheumatology·Kevin L WinthropEustratios Bananis
May 14, 2018·Clinical Reviews in Allergy & Immunology·Alexandra Leonard, Emma Guttman-Yassky
Mar 20, 2019·BMC Rheumatology·Julie M ParmentierAndrew J Long
Jun 14, 2019·Clinical Pharmacology and Therapeutics·Mohamed-Eslam F MohamedAhmed A Othman
Oct 24, 2019·Drugs·Sean Duggan, Susan J Keam
Dec 2, 2019·The Journal of Allergy and Clinical Immunology·Emma Guttman-YasskyJonathan I Silverberg

❮ Previous
Next ❯

Citations

May 28, 2021·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kunihiro YamaokaTsutomu Takeuchi
Jun 26, 2021·Acta Biochimica Et Biophysica Sinica·Huiyan ZhenYan Guo
Dec 4, 2021·Expert Review of Clinical Immunology·Maryam A AdasKatie Bechman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

© 2022 Meta ULC. All rights reserved